Bempegaldesleukin-Opdivo Combo Leads to Prolonged Responses in TNBC Patients, Phase 1/2 Trial Shows

Bempegaldesleukin-Opdivo Combo Leads to Prolonged Responses in TNBC Patients, Phase 1/2 Trial Shows
Bempegaldesleukin (bempeg, NKTR-214) in combination with Opdivo (nivolumab) leads to prolonged treatment responses in women with advanced or metastatic triple-negative breast cancer (TNBC), a Phase 1/2 trial shows. The findings were presented in a poster titled, "Clinical activity of BEMPEG plus NIVO observed in metastatic TNBC: preliminary results from the TNBC cohort of the Ph1/2 PIVOT-02 study," at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, held Sept. 25-28 in Paris. Bempegaldesleukin, developed by Nektar Therapeutics, is an investigational first-in-class agent that targets CD122, a protein found on the surface of immune T cells and natural killer (NK) cells. It works by activating and stimulating the growth of these cancer-killing immune cells, without over-activating the entire immune system. PIVOT-02 (NCT02983045) is a multi-center, open-label, Phase 1/2 trial that is assessing the safety and efficacy of bempegaldesleukin in combination with Opdivo, an immune checkpoint inhibitor developed by Brist
Subscribe or to access all post and page content.